LIC divests 2% stake in Sun Pharma

| Leave a Comment | Stocks

Life Insurance Corporation of India (LIC) has divested a 2.011% stake in Sun Pharmaceutical Industries Ltd., reducing its holding from 5.023% to 3.012%.

The transaction was done through the open market between July 22 and September 13 at an average floor price of Rs 973.80 per share.

Sun Pharmaceutical Industries Ltd had reported a net profit of Rs 2,022.54 crore for the quarter ended June 2023, down 1.86% from Rs 2,060.88 crore in the same period last year.

LIC’s stake sale comes at a time when the company is facing some challenges. In July, the US Food and Drug Administration (FDA) issued a warning letter to one of Sun Pharma’s manufacturing facilities in Halol, Gujarat. The FDA said that the facility had failed to comply with certain good manufacturing practices.

LIC’s stake sale in Sun Pharma is also part of a broader trend of insurance companies reducing their exposure to the pharmaceutical sector. In recent years, insurance companies have been selling off their stakes in pharmaceutical companies as they look to invest in other sectors, such as technology and infrastructure.

The disclaimer at the end of the article is important to note. It reminds readers that the views and investment tips expressed by experts are their own and should not be taken as investment advice.


Related News

  • 22 Sep

    NBCC shares trade higher on Rs 100 crore work order from SAIL

    NBCC shares were trading 3 percent higher on September 22 after the company announced having bagged a work order worth Rs 100 crore from SAIL. This is the fourth order-win announced by the company in this month, the total value of the same being Rs 450 crore. NBCC is a public sector undertaking engaged in the business of construction and real estate development. The company specializes in providing project management, consultancy and engineering services for civil construction, infrastructure development, and real estate projects.

  • 22 Sep

    Glenmark Pharma stock falls on stake sale in Glenmark Life Sciences

    Glenmark Pharma stock fell after the company announced it would sell a 75% stake in its subsidiary Glenmark Life Sciences to Nirma. Analysts expect the stake sale to benefit Glenmark Pharma, as it will transition from a net debt position to a cash surplus position. This is expected to have a positive impact on the company's return ratios over the next two to three years.

  • 22 Sep

    Berger Paints Shares Hit 52-Week High After Turning Ex-Bonus

    Berger Paints shares surged 6% to hit a 52-week high after turning ex-bonus on the record date for the issue of bonus shares in the ratio 1:5. The company posted a net profit of Rs 326.3 crore in the April-June quarter of FY24, up 39% year-on-year, on revenue of Rs 2,739.7 crore, up 10% year-on-year. The company expects to get net cash positive by the end of this fiscal year and expects to end the year with double-digit revenue growth on strong demand outlook.

  • 22 Sep

    Market Update for September 22, 2023

    IdeaForge Tech up 3.4% on order RVNL up 3% on highway MoU JSW Steel up 0.4% on sale ICICI Lombard down 1.6% on CEO exit ICICI Bank down 1% on healthcare investment NHPC up 1.3% on extended additional charge Kalyani Forge up 3.2% on new MD IRB Infra up 2.5% on road project closure

  • 22 Sep

    Lux Industries Shares Down 3% After Income Tax Raid

    Lux Industries shares fell 3% on September 22 after news emerged that the Income Tax department had conducted searches at the company's premises in Kolkata and alleged a tax evasion of Rs 200 crore. The company has confirmed the searches and is extending full support.

Leave a Reply

Your email address will not be published. Required fields are marked *